Limits...
Changes in oxidant-antioxidant status in young diabetic patients from clinical onset onwards.

Martín-Gallán P, Carrascosa A, Gussinyé M, Domínguez C - J. Cell. Mol. Med. (2007 Nov-Dec)

Bottom Line: Plasma levels of oxidizable lipids were significantly associated with lipid and protein oxidation products.Overall, plasma antioxidant capacity was significantly and consistently lower from clinical onset onwards.Consequently, tight lipid and glycometabolic control may have therapeutic potential by diminishing oxidative tissue-damaging effects of hyperglycaemia.

View Article: PubMed Central - PubMed

Affiliation: Biochemistry and Molecular Biology Research Center, Autonomous University, Barcelona, Spain.

ABSTRACT
Oxidative stress has been implicated as a mechanism underlying hyperglycaemia-associated cellular damage and could play a role in the development of diabetes-related complications. This study aimed to evaluate the significance of changes in oxidant-antioxidant status in 176 child and adolescent diabetic patients at clinical onset, during disease progression and when early microvascular complications appeared. Indicative lipid and protein oxidation markers and antioxidant defence activity were measured in plasma and correlated with clinical data, diabetes duration, long-term glycometabolic control and serum lipids. Compared with their respective age-matched controls, diabetic patients had greater oxidative damage to lipids and proteins, demonstrated through the analysis of hydroperoxides, lipoperoxides and oxidation protein products, all of which were significantly raised at onset, decreased during the first 1.5 years of evolution and rose progressively thereafter. Plasma levels of oxidizable lipids were significantly associated with lipid and protein oxidation products. Overall, plasma antioxidant capacity was significantly and consistently lower from clinical onset onwards. These results suggest that insulin therapy in the first year improved metabolic and oxidant homeostasis and consequently hyperglycaemia-derived biomolecular oxidative damage. Diabetes-associated hyperlipidaemia is related to lipid and protein oxidation processes, which supports the concept of glucose toxicity and lipotoxicity being interrelated. The greatest increase in lipid and protein oxidative damage biomarkers in young diabetic patients with premature microangiopathy points to oxidative stress as a possible contributing mechanism of microvascular dysfunction. Consequently, tight lipid and glycometabolic control may have therapeutic potential by diminishing oxidative tissue-damaging effects of hyperglycaemia.

Show MeSH

Related in: MedlinePlus

Plasma advanced oxidation protein products (AOPP) (A) in diabetic patients at disease onset [DO], during the first 20 years of disease evolution [four subgroups: <1.5, 1.5–5, 5–10, 10–20], in diabetic patients with complications [+DC] and in their respective controls; filled columns: diabetic patients data; open columns: control data. Correlation between plasma AOPP and total lipid concentrations in plasma (B). Values are expressed as mean ± SEM and were analysed for statistically-significant differences by analysis of variance (ANOVA); P values <0.05 (versusrespective control participants) were considered significant and are shown above each subgroup in the graph. * P<0.05 diabetic patients with complications [+DC] versus[10–20] subgroup of patients.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4401297&req=5

fig03: Plasma advanced oxidation protein products (AOPP) (A) in diabetic patients at disease onset [DO], during the first 20 years of disease evolution [four subgroups: <1.5, 1.5–5, 5–10, 10–20], in diabetic patients with complications [+DC] and in their respective controls; filled columns: diabetic patients data; open columns: control data. Correlation between plasma AOPP and total lipid concentrations in plasma (B). Values are expressed as mean ± SEM and were analysed for statistically-significant differences by analysis of variance (ANOVA); P values <0.05 (versusrespective control participants) were considered significant and are shown above each subgroup in the graph. * P<0.05 diabetic patients with complications [+DC] versus[10–20] subgroup of patients.

Mentions: Plasma AOPP, markers of protein oxidation, were significantly higher (P<0.0005) in samples from [DO], [5–10D] and [10–20D] groups and higher still in the group of diabetic patients with complications compared with their respective age-matched controls (Fig. 3A). Linear regression analysis of plasma AOPP showed positive correlations with both triglycerides (r = 0.42; P<0.0005) and total lipids (Fig. 3B).


Changes in oxidant-antioxidant status in young diabetic patients from clinical onset onwards.

Martín-Gallán P, Carrascosa A, Gussinyé M, Domínguez C - J. Cell. Mol. Med. (2007 Nov-Dec)

Plasma advanced oxidation protein products (AOPP) (A) in diabetic patients at disease onset [DO], during the first 20 years of disease evolution [four subgroups: <1.5, 1.5–5, 5–10, 10–20], in diabetic patients with complications [+DC] and in their respective controls; filled columns: diabetic patients data; open columns: control data. Correlation between plasma AOPP and total lipid concentrations in plasma (B). Values are expressed as mean ± SEM and were analysed for statistically-significant differences by analysis of variance (ANOVA); P values <0.05 (versusrespective control participants) were considered significant and are shown above each subgroup in the graph. * P<0.05 diabetic patients with complications [+DC] versus[10–20] subgroup of patients.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4401297&req=5

fig03: Plasma advanced oxidation protein products (AOPP) (A) in diabetic patients at disease onset [DO], during the first 20 years of disease evolution [four subgroups: <1.5, 1.5–5, 5–10, 10–20], in diabetic patients with complications [+DC] and in their respective controls; filled columns: diabetic patients data; open columns: control data. Correlation between plasma AOPP and total lipid concentrations in plasma (B). Values are expressed as mean ± SEM and were analysed for statistically-significant differences by analysis of variance (ANOVA); P values <0.05 (versusrespective control participants) were considered significant and are shown above each subgroup in the graph. * P<0.05 diabetic patients with complications [+DC] versus[10–20] subgroup of patients.
Mentions: Plasma AOPP, markers of protein oxidation, were significantly higher (P<0.0005) in samples from [DO], [5–10D] and [10–20D] groups and higher still in the group of diabetic patients with complications compared with their respective age-matched controls (Fig. 3A). Linear regression analysis of plasma AOPP showed positive correlations with both triglycerides (r = 0.42; P<0.0005) and total lipids (Fig. 3B).

Bottom Line: Plasma levels of oxidizable lipids were significantly associated with lipid and protein oxidation products.Overall, plasma antioxidant capacity was significantly and consistently lower from clinical onset onwards.Consequently, tight lipid and glycometabolic control may have therapeutic potential by diminishing oxidative tissue-damaging effects of hyperglycaemia.

View Article: PubMed Central - PubMed

Affiliation: Biochemistry and Molecular Biology Research Center, Autonomous University, Barcelona, Spain.

ABSTRACT
Oxidative stress has been implicated as a mechanism underlying hyperglycaemia-associated cellular damage and could play a role in the development of diabetes-related complications. This study aimed to evaluate the significance of changes in oxidant-antioxidant status in 176 child and adolescent diabetic patients at clinical onset, during disease progression and when early microvascular complications appeared. Indicative lipid and protein oxidation markers and antioxidant defence activity were measured in plasma and correlated with clinical data, diabetes duration, long-term glycometabolic control and serum lipids. Compared with their respective age-matched controls, diabetic patients had greater oxidative damage to lipids and proteins, demonstrated through the analysis of hydroperoxides, lipoperoxides and oxidation protein products, all of which were significantly raised at onset, decreased during the first 1.5 years of evolution and rose progressively thereafter. Plasma levels of oxidizable lipids were significantly associated with lipid and protein oxidation products. Overall, plasma antioxidant capacity was significantly and consistently lower from clinical onset onwards. These results suggest that insulin therapy in the first year improved metabolic and oxidant homeostasis and consequently hyperglycaemia-derived biomolecular oxidative damage. Diabetes-associated hyperlipidaemia is related to lipid and protein oxidation processes, which supports the concept of glucose toxicity and lipotoxicity being interrelated. The greatest increase in lipid and protein oxidative damage biomarkers in young diabetic patients with premature microangiopathy points to oxidative stress as a possible contributing mechanism of microvascular dysfunction. Consequently, tight lipid and glycometabolic control may have therapeutic potential by diminishing oxidative tissue-damaging effects of hyperglycaemia.

Show MeSH
Related in: MedlinePlus